Actively Recruiting
Clinical Characteristics and Treatment Outcomes in Patients with Axial Spondyloarthritis and Psoriatic Arthritis Starting Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or TNF Inhibitors
Led by Adelphi Real World · Updated on 2026-10-27
700
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate treatment effectiveness in patients with axial spondyloarthritis axSpA and psoriatic arthritis PsA who have begun treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or tumor necrosis factor-alpha inhibitors such as adalimumab or etanercept. The study collects information from patients at NHS hospitals in the United Kingdom to understand treatment impact from both medical professionals and patients perspectives. The study is observational, meaning no new treatments are given as part of the research. Patients have already started one of the advanced therapies prescribed for their condition within one month before joining. Patient experience surveys are collected throughout the study, while medical records are reviewed retrospectively at the end of the study period. Participants will complete surveys during the study to share their treatment experiences, while researchers will analyze medical records after the study concludes. The main outcomes measured include the number of patients achieving low disease activity and minimal disease activity at 12 months, as well as changes in patient-reported outcome measures compared to baseline. The study lasts approximately two years from 2025 to 2027.
CONDITIONS
Brief Title
Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
Research Team
S
SpA Extend Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here